Abstract: TH-PO1273
Niaoduqing Granules Improve Constipation in Patients with Peritoneal Dialysis: A Multicenter Prospective Controlled Study
Session Information
- Late-Breaking Research Posters
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 802 Dialysis: Home Dialysis and Peritoneal Dialysis
Authors
- Li, Miao, Peking University People's Hospital, Beijing, China
- Zhao, Huiping, Peking University People's Hospital, Beijing, China
- Zhao, Bin, Beijing Haidian Hospital, Beijing, China
- Yue, Lingju, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
- Ding, Jiaxiang, Peking University International Hospital, Beijing, China
- Zhao, Wei, Peking University Shougang Hospital, Beijing, China
- Liu, Xuejiao, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, China
- Fu, Gang, Beijing Haidian Hospital, Beijing, China
- Li, Zhongxin, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
- Yu, Feng, Peking University International Hospital, Beijing, China
- Zhao, Haidan, Peking University Shougang Hospital, Beijing, China
- Cai, Jianfang, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, China
- Zuo, Li, Peking University People's Hospital, Beijing, China
Background
Constipation is common in patients receiving peritoneal dialysis (PD) and may be associated with alterations in the gut microbiome and metabolism. We evaluated the effects of 24-week Niaoduqing granule treatment on constipation, gut microbiota, fecal metabolism, and gut-derived uremic toxins.
Methods
In this multicenter prospective controlled study, 40 PD patients with constipation received Niaoduqing granules for 24 weeks; 20 nonconstipated PD patients and 10 healthy participants served as controls. Constipation was diagnosed using the Rome III criteria, Wexner Constipation Score, and Bristol Stool Form Scale. Serum indoxyl sulfate (IS) and p-cresyl sulfate (PCS), gut metagenomics, and untargeted fecal metabolomics were assessed. Pruritus, residual kidney function, inflammatory markers, and safety were secondary outcomes.
Results
Thirty-three patients completed 24 weeks of treatment. Bristol stool form improved from a median of 2.0 at baseline to 4.0 at both weeks 12 and 24, while Wexner score decreased from 9.0 to 4.0 and 3.0, respectively (both P<0.001). Compared with healthy controls, PD patients had markedly higher serum IS and PCS levels, along with differences in gut microbial and fecal metabolomic profiles. Among PD patients, those with and without constipation differed in fecal metabolomic profiles, whereas microbial diversity and serum IS/PCS were similar. Serum IS and PCS did not change significantly during treatment, while improvement in Bristol stool form correlated with PCS reduction at week 24 (ρ=0.41). At week 24, the relative abundances of the potentially beneficial genera Blautia and Anaerostipes increased compared with baseline. Fecal metabolomic analysis suggested changes involving amino acid-related pathways. In addition, pruritus improved markedly, whereas residual kidney function and inflammatory markers remained stable. No serious adverse events occurred.
Conclusion
Niaoduqing granules improved constipation and pruritus over 24 weeks and were accompanied by changes in gut microbial and fecal metabolic profiles. Although serum IS and PCS did not decrease overall, greater improvement in stool form was correlated with greater PCS reduction.